FACE study


The FACE study is a French and Belgium prospective, multicentre, observational cohort that will provide long-term data on morbidity and mortality of heart failure (both HFrEF and HFpEF) patients using ASV. So far over 400 patients have been enrolled by 30 centres. Since May 2015, the recruitment has been limited to patients with HFpEF, with a target of 300 chronic HFpEF patients. 

Interim data results



Interim data from the FACE cohort seems to confirm these findings1, and provide some positive insights in HFpEF:

  • The FACE prospective cohort aimed to provide real-world data about the prognosis of HF patients with CSA treated with ASV. This interim analysis provides some long-term morbidity and mortality data of 391 HF patients (HFrEF, HFmrEF or HFpEF) eligible to ASV therapy followed during 2 years.
  • Severe hypoxemia (high T90) during sleep is a strong independent risk factor for mortality in HF patients (HR=12).
  • ASV therapy was associated with a better prognosis in CHF patients with severe nocturnal hypoxaemia or non-ischemic etiology, especially in subgroups with middle-range or preserved LVEF but not with reduced LVEF.

More about SDB research

There’s a growing body of clinical research that demonstrates the efficacy and compliance of mandibular repositioning devices (MRDs) in treating obstructive sleep apnoea and snoring.

Read more

Sleep apnoea and digital connected health

A growing body of research shows that connected health brings results. Improved compliance, greater efficiencies, higher quality of care – here is some of the latest research that provides evidence of these results.

Support for investigator initiated research

ResMed believes in the need to support ethical, independent clinical research, conducted by qualified third-party investigators.



  1. R Tamisier et al: Late Breaking Abstract – Morbidity and mortality of chronic heart failure (CHF) patients with central sleep apnoea (CSA) treated by adaptive servoventilation (ASV): Interim results of FACE cohort study_Update. ERJ September 2017 Supplement.